Switch to:
Also traded in: Germany, Singapore, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.15
LZAGY's Cash to Debt is ranked lower than
83% of the 1080 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.83 vs. LZAGY: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
LZAGY' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.14 Max: No Debt
Current: 0.15
Equity to Asset 0.33
LZAGY's Equity to Asset is ranked lower than
80% of the 992 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.53 vs. LZAGY: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
LZAGY' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.33 Max: 0.5
Current: 0.33
0.3
0.5
Interest Coverage 7.40
LZAGY's Interest Coverage is ranked lower than
73% of the 941 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 32.28 vs. LZAGY: 7.40 )
Ranked among companies with meaningful Interest Coverage only.
LZAGY' s Interest Coverage Range Over the Past 10 Years
Min: 2.13  Med: 5.18 Max: 7.63
Current: 7.4
2.13
7.63
F-Score: 6
Z-Score: 2.71
M-Score: -2.92
WACC vs ROIC
8.30%
11.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.48
LZAGY's Operating margin (%) is ranked higher than
79% of the 1055 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 6.51 vs. LZAGY: 13.48 )
Ranked among companies with meaningful Operating margin (%) only.
LZAGY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.06  Med: 11.44 Max: 15.02
Current: 13.48
7.06
15.02
Net-margin (%) 9.19
LZAGY's Net-margin (%) is ranked higher than
75% of the 1058 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.45 vs. LZAGY: 9.19 )
Ranked among companies with meaningful Net-margin (%) only.
LZAGY' s Net-margin (%) Range Over the Past 10 Years
Min: 2.43  Med: 6.9 Max: 14.27
Current: 9.19
2.43
14.27
ROE (%) 17.57
LZAGY's ROE (%) is ranked higher than
79% of the 1047 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 7.75 vs. LZAGY: 17.57 )
Ranked among companies with meaningful ROE (%) only.
LZAGY' s ROE (%) Range Over the Past 10 Years
Min: 4.11  Med: 11.75 Max: 22.52
Current: 17.57
4.11
22.52
ROA (%) 5.81
LZAGY's ROA (%) is ranked higher than
64% of the 1083 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 3.85 vs. LZAGY: 5.81 )
Ranked among companies with meaningful ROA (%) only.
LZAGY' s ROA (%) Range Over the Past 10 Years
Min: 1.3  Med: 4.04 Max: 7.45
Current: 5.81
1.3
7.45
ROC (Joel Greenblatt) (%) 39.47
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 1075 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 12.15 vs. LZAGY: 39.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LZAGY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.93  Med: 12.67 Max: 39.47
Current: 39.47
7.93
39.47
Revenue Growth (3Y)(%) -1.50
LZAGY's Revenue Growth (3Y)(%) is ranked lower than
64% of the 941 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.10 vs. LZAGY: -1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LZAGY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.5  Med: 7.9 Max: 12.8
Current: -1.5
-5.5
12.8
EBITDA Growth (3Y)(%) 3.30
LZAGY's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 830 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 8.10 vs. LZAGY: 3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LZAGY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.4  Med: 3.3 Max: 20.9
Current: 3.3
-12.4
20.9
EPS Growth (3Y)(%) 16.20
LZAGY's EPS Growth (3Y)(%) is ranked higher than
62% of the 739 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 8.10 vs. LZAGY: 16.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LZAGY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: 1.9 Max: 28.2
Current: 16.2
-32.9
28.2
» LZAGY's 10-Y Financials

Financials (Next Earnings Date: 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Chemicals » Specialty Chemicals
Compare:OTCPK:SYIEY, NYSE:IFF, NYSE:ALB, OTCPK:ALFFF, OTCPK:NDEKY, OTCPK:JMPLF, NYSE:VAL, OTCPK:CHYHY, OTCPK:RDSMY, OTCPK:BNTGY, NYSE:RPM, OTCPK:ARKAY, NYSE:AXTA, NYSE:WLK, OTCPK:COIHY, OTCPK:CLZNY, NYSE:GRA, NYSE:NEU, OTCPK:LNXSF, OTCPK:EVKIF » details
Traded in other countries:LO3.Germany, O6Z.Singapore, LONN.Switzerland, 0QNO.UK,
Lonza Group AG is a supplier of biopharmaceuticals to the pharmaceutical and biotechnology industries. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients.

Lonza Group Ltd was founded in 1897. The Company supplies biopharmaceuticals to the Pharma&Biotech and Specialty Ingredient markets. Its products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients. In the Specialty Ingredients segment, the Company supply solutions that promote health, wellness, beauty, nutrition, hygiene and materials protection. It also offers Industrial Solutions, including preservatives and biocide blends that deter the growth of mold, mildew and/or other contaminants on painted and coated surfaces, bath mats, carpeting, wallboard, flooring and ceiling materials, and in adhesives and sealants. The Water Treatment business within Specialty Ingredients is a supplier of sanitizers and other treatment chemicals for pools, spas and water parks. In addition, the Company offers top-of-the-line feeder systems to deliver clean drinking water, maintain and enhance surface water, and provide sanitizing solutions within the agriculture industry. The Pharma & Biotech segment encompasses Custom Development and Custom Manufacturing offerings to the Pharma & Biotech market, as well as offerings from the Company's Bioscience Solutions business to its BioResearch market. The Bioscience Solutions provides tools for two distinct business areas: research and disease-discovery tools for research in academic and industrial research facilities across the world, as well as solutions for pharmaceutical and biopharmaceutical manufacturing, which includes emerging technologies such as cell and viral therapy.

Ratios

vs
industry
vs
history
P/E(ttm) 27.25
LZAGY's P/E(ttm) is ranked lower than
67% of the 841 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 17.92 vs. LZAGY: 27.25 )
Ranked among companies with meaningful P/E(ttm) only.
LZAGY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.61  Med: 22.82 Max: 69.7
Current: 27.25
8.61
69.7
Forward P/E 23.64
LZAGY's Forward P/E is ranked lower than
77% of the 94 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 17.57 vs. LZAGY: 23.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.25
LZAGY's PE(NRI) is ranked lower than
67% of the 842 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 17.96 vs. LZAGY: 27.25 )
Ranked among companies with meaningful PE(NRI) only.
LZAGY' s PE(NRI) Range Over the Past 10 Years
Min: 8.61  Med: 22.82 Max: 69.7
Current: 27.25
8.61
69.7
Price/Owner Earnings (ttm) 25.13
LZAGY's Price/Owner Earnings (ttm) is ranked lower than
63% of the 471 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 17.56 vs. LZAGY: 25.13 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LZAGY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.22  Med: 81.46 Max: 243.12
Current: 25.13
9.22
243.12
P/B 4.73
LZAGY's P/B is ranked lower than
83% of the 987 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.71 vs. LZAGY: 4.73 )
Ranked among companies with meaningful P/B only.
LZAGY' s P/B Range Over the Past 10 Years
Min: 0.81  Med: 2.21 Max: 4.79
Current: 4.73
0.81
4.79
P/S 2.56
LZAGY's P/S is ranked lower than
74% of the 1032 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.14 vs. LZAGY: 2.56 )
Ranked among companies with meaningful P/S only.
LZAGY' s P/S Range Over the Past 10 Years
Min: 0.63  Med: 1.54 Max: 2.61
Current: 2.56
0.63
2.61
PFCF 20.55
LZAGY's PFCF is ranked lower than
63% of the 377 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 15.75 vs. LZAGY: 20.55 )
Ranked among companies with meaningful PFCF only.
LZAGY' s PFCF Range Over the Past 10 Years
Min: 6.17  Med: 18.96 Max: 211.68
Current: 20.55
6.17
211.68
POCF 13.23
LZAGY's POCF is ranked lower than
69% of the 480 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 9.19 vs. LZAGY: 13.23 )
Ranked among companies with meaningful POCF only.
LZAGY' s POCF Range Over the Past 10 Years
Min: 3.47  Med: 10.27 Max: 36.19
Current: 13.23
3.47
36.19
EV-to-EBIT 26.70
LZAGY's EV-to-EBIT is ranked lower than
73% of the 858 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 14.16 vs. LZAGY: 26.70 )
Ranked among companies with meaningful EV-to-EBIT only.
LZAGY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 19.1 Max: 32.6
Current: 26.7
8.4
32.6
EV-to-EBITDA 15.65
LZAGY's EV-to-EBITDA is ranked lower than
64% of the 895 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 10.70 vs. LZAGY: 15.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
LZAGY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.8 Max: 16.1
Current: 15.65
4.9
16.1
PEG 13.11
LZAGY's PEG is ranked lower than
89% of the 431 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.14 vs. LZAGY: 13.11 )
Ranked among companies with meaningful PEG only.
LZAGY' s PEG Range Over the Past 10 Years
Min: 0.55  Med: 3.22 Max: 16.52
Current: 13.11
0.55
16.52
Shiller P/E 38.62
LZAGY's Shiller P/E is ranked lower than
62% of the 176 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 32.01 vs. LZAGY: 38.62 )
Ranked among companies with meaningful Shiller P/E only.
LZAGY' s Shiller P/E Range Over the Past 10 Years
Min: 19.36  Med: 29.34 Max: 39.12
Current: 38.62
19.36
39.12
Current Ratio 1.49
LZAGY's Current Ratio is ranked lower than
60% of the 943 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.75 vs. LZAGY: 1.49 )
Ranked among companies with meaningful Current Ratio only.
LZAGY' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.31 Max: 2.02
Current: 1.49
0.94
2.02
Quick Ratio 1.49
LZAGY's Quick Ratio is ranked higher than
59% of the 943 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.29 vs. LZAGY: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
LZAGY' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 0.94 Max: 2.02
Current: 1.49
0.6
2.02
Days Inventory 82.41
LZAGY's Days Inventory is ranked lower than
65% of the 1015 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 66.10 vs. LZAGY: 82.41 )
Ranked among companies with meaningful Days Inventory only.
LZAGY' s Days Inventory Range Over the Past 10 Years
Min: 82.41  Med: 112.3 Max: 123.17
Current: 82.41
82.41
123.17
Days Sales Outstanding 50.12
LZAGY's Days Sales Outstanding is ranked higher than
64% of the 812 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 60.38 vs. LZAGY: 50.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
LZAGY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.12  Med: 60.43 Max: 94.23
Current: 50.12
50.12
94.23
Days Payable 40.31
LZAGY's Days Payable is ranked lower than
57% of the 780 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 45.67 vs. LZAGY: 40.31 )
Ranked among companies with meaningful Days Payable only.
LZAGY' s Days Payable Range Over the Past 10 Years
Min: 29.47  Med: 37.08 Max: 53.87
Current: 40.31
29.47
53.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.33
LZAGY's Dividend Yield is ranked lower than
69% of the 1051 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.11 vs. LZAGY: 1.33 )
Ranked among companies with meaningful Dividend Yield only.
LZAGY' s Dividend Yield Range Over the Past 10 Years
Min: 0.96  Med: 2.21 Max: 6.38
Current: 1.33
0.96
6.38
Dividend Payout 0.37
LZAGY's Dividend Payout is ranked lower than
55% of the 697 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.33 vs. LZAGY: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
LZAGY' s Dividend Payout Range Over the Past 10 Years
Min: 0.34  Med: 0.8 Max: 2.72
Current: 0.37
0.34
2.72
Dividend Growth (3y) -100.00
LZAGY's Dividend Growth (3y) is ranked lower than
91% of the 549 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 5.70 vs. LZAGY: -100.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
LZAGY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -100  Med: 7.1 Max: 10.4
Current: -100
-100
10.4
Forward Dividend Yield 1.32
LZAGY's Forward Dividend Yield is ranked lower than
72% of the 1019 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.20 vs. LZAGY: 1.32 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.33
LZAGY's Yield on cost (5-Year) is ranked lower than
65% of the 1199 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.48 vs. LZAGY: 1.33 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LZAGY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.96  Med: 2.21 Max: 6.38
Current: 1.33
0.96
6.38
3-Year Average Share Buyback Ratio -0.20
LZAGY's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 469 Companies
in the Global Specialty Chemicals industry.

( Industry Median: -1.60 vs. LZAGY: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LZAGY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.3  Med: -0.1 Max: 1.5
Current: -0.2
-3.3
1.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.74
LZAGY's Price/Tangible Book is ranked lower than
77% of the 943 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.82 vs. LZAGY: 4.74 )
Ranked among companies with meaningful Price/Tangible Book only.
LZAGY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.86  Med: 3.32 Max: 47.44
Current: 4.74
0.86
47.44
Price/Projected FCF 2.14
LZAGY's Price/Projected FCF is ranked lower than
99.99% of the 497 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.24 vs. LZAGY: 2.14 )
Ranked among companies with meaningful Price/Projected FCF only.
LZAGY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0  Med: 2.11 Max: 2.88
Current: 2.14
0
2.88
Price/Median PS Value 1.67
LZAGY's Price/Median PS Value is ranked lower than
99.99% of the 986 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.21 vs. LZAGY: 1.67 )
Ranked among companies with meaningful Price/Median PS Value only.
LZAGY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0  Med: 0.96 Max: 1.69
Current: 1.67
0
1.69
Price/Graham Number 2.40
LZAGY's Price/Graham Number is ranked lower than
72% of the 686 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.19 vs. LZAGY: 2.40 )
Ranked among companies with meaningful Price/Graham Number only.
LZAGY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.75  Med: 1.65 Max: 7.99
Current: 2.4
0.75
7.99
Earnings Yield (Greenblatt) (%) 3.71
LZAGY's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 1057 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 5.30 vs. LZAGY: 3.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LZAGY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.1  Med: 5.2 Max: 12
Current: 3.71
3.1
12
Forward Rate of Return (Yacktman) (%) 5.40
LZAGY's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 568 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.20 vs. LZAGY: 5.40 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LZAGY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.1  Med: 3.5 Max: 17
Current: 5.4
-5.1
17

More Statistics

Revenue (TTM) (Mil) $3,991
EPS (TTM) $ 0.70
Beta1.13
Short Percentage of Float0.00%
52-Week Range $12.83 - 19.65
Shares Outstanding (Mil)522.83

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 4,157 4,383
EPS ($) 0.82 0.96
EPS w/o NRI ($) 0.82 0.96
EPS Growth Rate
(3Y to 5Y Estimate)
12.49%
Dividends Per Share ($) 0.26 0.26
» More Articles for LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Business Highlights Aug 15 2016
Business Highlights Aug 15 2016
Lonza buys InterHealth in health push Aug 15 2016
Lonza buys InterHealth in health push Aug 15 2016
Swiss Lonza buys US diet supplement supplier InterHealth Aug 15 2016
Swiss Lonza buys US diet supplement supplier InterHealth Aug 15 2016
Lonza to Acquire InterHealth for as Much as $300 Million Aug 15 2016
Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals Aug 15 2016
Lonza Group AG :LZAGY-US: Earnings Analysis: For the six months ended June 30, 2016 : July 26, 2016 Jul 26 2016
ETF’s with exposure to Lonza Group AG : July 21, 2016 Jul 21 2016
European shares rise on strong results from SAP and Lonza Jul 20 2016
European shares rise on strong results from SAP and Lonza Jul 20 2016
Lonza Raises 2016 Outlook as Profit Jumps on Savings, Demand Jul 20 2016
New e-Learning Module in the Lonza QC Insider TM Toolbox Helps Scientists Overcome Interference in... Jul 12 2016
ETF’s with exposure to Lonza Group AG : July 6, 2016 Jul 06 2016
Lonza Group AG :LZAGY-US: Earnings Analysis: For the six months ended December 31, 2015 : July 4,... Jul 04 2016
Lonza Acquires Triangle Research Labs, a Hepatocyte Provider Based in North Carolina (USA) Jun 30 2016
Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for... Jun 09 2016
Lonza’s 4D-Nucleofector TM LV Unit Delivers Closed, Optimized, Larger-Scale Transfection Jun 08 2016
Lonza Announces 25 th Approved Biotherapeutic Using the GS Gene Expression System™ Jun 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)